JP2023106403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023106403A5 JP2023106403A5 JP2023072147A JP2023072147A JP2023106403A5 JP 2023106403 A5 JP2023106403 A5 JP 2023106403A5 JP 2023072147 A JP2023072147 A JP 2023072147A JP 2023072147 A JP2023072147 A JP 2023072147A JP 2023106403 A5 JP2023106403 A5 JP 2023106403A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- ceutically acceptable
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 206010069351 acute lung injury Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776837P | 2018-12-07 | 2018-12-07 | |
| US62/776,837 | 2018-12-07 | ||
| JP2021532311A JP7594787B2 (ja) | 2018-12-07 | 2019-12-06 | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532311A Division JP7594787B2 (ja) | 2018-12-07 | 2019-12-06 | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023106403A JP2023106403A (ja) | 2023-08-01 |
| JP2023106403A5 true JP2023106403A5 (enExample) | 2025-04-10 |
Family
ID=70974384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532311A Active JP7594787B2 (ja) | 2018-12-07 | 2019-12-06 | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| JP2023072147A Pending JP2023106403A (ja) | 2018-12-07 | 2023-04-26 | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532311A Active JP7594787B2 (ja) | 2018-12-07 | 2019-12-06 | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11078171B2 (enExample) |
| EP (2) | EP3890733B1 (enExample) |
| JP (2) | JP7594787B2 (enExample) |
| CN (1) | CN113395963B (enExample) |
| AU (3) | AU2019392904B9 (enExample) |
| CA (1) | CA3122371A1 (enExample) |
| ES (1) | ES3025468T3 (enExample) |
| IL (1) | IL283755A (enExample) |
| MX (2) | MX2021006731A (enExample) |
| WO (1) | WO2020118194A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7013453B2 (ja) | 2016-06-23 | 2022-01-31 | ユニバーシティ・オブ・メリーランド・ボルティモア | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| IL298366A (en) | 2020-05-18 | 2023-01-01 | Gen1E Lifesciences Inc | P38 alpha mitogen-activated protein kinase inhibitors, compositions comprising same and uses thereof |
| JP2023546835A (ja) * | 2020-10-29 | 2023-11-08 | ジーニー ライフサイエンシズ インコーポレイテッド | 結晶性５－（ジメチルアミノ）－ｎ－（４－（モルホリノメチル）フェニル）ナフタレン－１－スルホンアミド二塩酸塩二水和物 |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| IL306101A (en) * | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
| UY39681A (es) | 2021-03-26 | 2022-10-31 | Novartis Ag | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
| WO2023111996A1 (en) | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| IL321433A (en) | 2022-12-16 | 2025-08-01 | Astrazeneca Ab | Purines 2,6,9 trimethylated |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| CN116621794B (zh) * | 2023-05-22 | 2025-03-11 | 上海大学 | 一种5-苄基-2-氨基-1,3-噻唑类衍生物及其合成方法与应用 |
| US12116353B1 (en) * | 2024-04-25 | 2024-10-15 | Genie Lifesciences Inc. | Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR96352E (fr) | 1967-12-29 | 1972-06-16 | Science Union & Cie | Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation. |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| DE19801646A1 (de) | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte alpha,beta-annellierte Butyrolactone |
| JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
| CA2368047A1 (en) | 1999-03-24 | 2000-09-28 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| PT1537116E (pt) * | 2002-09-04 | 2010-09-03 | Schering Corp | Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| EP1597259B1 (de) | 2003-02-13 | 2008-04-30 | Sanofi-Aventis Deutschland GmbH | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| JP2007532615A (ja) * | 2004-04-13 | 2007-11-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US7829560B2 (en) * | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
| US20090299063A1 (en) | 2005-03-29 | 2009-12-03 | Paul Shapiro | Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses Therefor |
| WO2008094319A2 (en) * | 2007-02-01 | 2008-08-07 | The Board Of Regents Of The University Of Texas Sytem | Methods and compositions of trail-death receptor agonists/activators |
| TW200904421A (en) | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| ES2427892T3 (es) * | 2008-02-29 | 2013-11-04 | Chroma Therapeutics Limited | Inhibidores de MAP quinasa p38 |
| AU2009313315A1 (en) | 2008-11-07 | 2011-06-30 | The Cleveland Clinic Foundation | Compounds and methods of promoting oligodendrocyte precursor differentiation |
| WO2010082912A1 (en) | 2009-01-15 | 2010-07-22 | Avalon Pharmaceuticals | Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| HUE065700T2 (hu) * | 2011-05-03 | 2024-06-28 | Agios Pharmaceuticals Inc | Piruvát-kináz aktivátorok terápiában történõ alkalmazásra |
| HK1217687A1 (zh) | 2013-01-15 | 2017-01-20 | Karl Alex MÜLLER | 利用紫外线辐射的氧化物的快速固态反应 |
| KR102283883B1 (ko) | 2013-04-02 | 2021-07-29 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제 |
| US9025712B2 (en) | 2013-07-30 | 2015-05-05 | Pixart Imaging Inc. | Sensor, clock frequency adjusting system and method thereof |
| EP3076974A1 (en) * | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| US9447076B2 (en) | 2014-02-14 | 2016-09-20 | Respivert Ltd. | Inhibitor of p38 map kinase |
| CN113620958A (zh) * | 2014-03-19 | 2021-11-09 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| GB201417168D0 (en) | 2014-09-29 | 2014-11-12 | Univ Hertfordshire Higher Education Corp | Compounds |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤 |
| US10858316B2 (en) * | 2015-07-10 | 2020-12-08 | University Of Maryland, Baltimore | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof |
| JP7013453B2 (ja) | 2016-06-23 | 2022-01-31 | ユニバーシティ・オブ・メリーランド・ボルティモア | 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法 |
| WO2018085348A1 (en) * | 2016-11-03 | 2018-05-11 | Actavalon, Inc. | Substituted quinolines and methods for treating cancer |
| TW201829381A (zh) | 2016-12-22 | 2018-08-16 | 美商拜奧馬林製藥公司 | 組蛋白脫乙醯基酶抑制劑 |
| KR20200104873A (ko) | 2017-12-06 | 2020-09-04 | 린 바이오사이언스, 피티와이 엘티디. | 튜불린 억제제 |
| JP7594787B2 (ja) * | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| WO2021183970A1 (en) | 2020-03-13 | 2021-09-16 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| IL298366A (en) | 2020-05-18 | 2023-01-01 | Gen1E Lifesciences Inc | P38 alpha mitogen-activated protein kinase inhibitors, compositions comprising same and uses thereof |
| IL306101A (en) | 2021-03-23 | 2023-11-01 | Gen1E Lifesciences Inc | Naphthyl-mutated p38 alpha mitogen-activated protein kinase inhibitors |
-
2019
- 2019-12-06 JP JP2021532311A patent/JP7594787B2/ja active Active
- 2019-12-06 WO PCT/US2019/064960 patent/WO2020118194A1/en not_active Ceased
- 2019-12-06 MX MX2021006731A patent/MX2021006731A/es unknown
- 2019-12-06 CA CA3122371A patent/CA3122371A1/en active Pending
- 2019-12-06 ES ES19893204T patent/ES3025468T3/es active Active
- 2019-12-06 EP EP19893204.8A patent/EP3890733B1/en active Active
- 2019-12-06 AU AU2019392904A patent/AU2019392904B9/en active Active
- 2019-12-06 EP EP25161840.1A patent/EP4606792A1/en active Pending
- 2019-12-06 CN CN201980091398.5A patent/CN113395963B/zh active Active
-
2020
- 2020-05-11 US US16/872,114 patent/US11078171B2/en active Active
-
2021
- 2021-06-06 IL IL283755A patent/IL283755A/en unknown
- 2021-06-07 MX MX2024004162A patent/MX2024004162A/es unknown
- 2021-06-16 US US17/349,468 patent/US11718595B2/en active Active
-
2022
- 2022-11-04 AU AU2022263608A patent/AU2022263608B2/en active Active
-
2023
- 2023-04-26 JP JP2023072147A patent/JP2023106403A/ja active Pending
- 2023-06-07 US US18/206,925 patent/US12202810B2/en active Active
-
2024
- 2024-05-22 AU AU2024203398A patent/AU2024203398A1/en active Pending
- 2024-12-05 US US18/970,196 patent/US20250100985A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023106403A5 (enExample) | ||
| US7709664B2 (en) | Coumarin derivatives useful as TNFα inhibitors | |
| JP2005531584A5 (enExample) | ||
| JP2016500111A5 (enExample) | ||
| JP2004535447A5 (enExample) | ||
| JP2006515310A5 (enExample) | ||
| JP2008501705A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP3162071B2 (ja) | サイトカイン阻害剤 | |
| JPWO2023060253A5 (enExample) | ||
| RU2005106356A (ru) | Новое соединение | |
| RU2007107935A (ru) | Полисульфатированные гликозиды и их соли | |
| JP2008526950A5 (enExample) | ||
| WO2018011376A1 (en) | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | |
| JP2011528030A5 (enExample) | ||
| CN104095858A (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 | |
| CN109232546B (zh) | 一种嘧啶磺酰胺类衍生物的医药用途 | |
| CN1127336C (zh) | 肺性心病治疗剂 | |
| JP2004536078A5 (enExample) | ||
| JP2018504391A5 (enExample) | ||
| JPWO2022261240A5 (enExample) | ||
| JPWO2021191592A5 (enExample) | ||
| JP2008520611A5 (enExample) | ||
| JP2021107447A5 (enExample) | ||
| CN104398525B (zh) | 闭花木酮的o-(哌嗪基)乙基衍生物在制备抗慢性阻塞性肺病药物中的应用 |